about
Killing tumours by ceramide-induced apoptosis: a critique of available drugsThe endocannabinoid system as an emerging target of pharmacotherapyHarm reduction--the cannabis paradoxMaternal Malnutrition in the Etiopathogenesis of Psychiatric Diseases: Role of Polyunsaturated Fatty AcidsFetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids SignalingReceptor heteromerization expands the repertoire of cannabinoid signaling in rodent neuronsDelta(9)-tetrahydrocannabinol regulates the p53 post-translational modifiers Murine double minute 2 and the Small Ubiquitin MOdifier protein in the rat brainThe Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination.Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice.Cannabinoids as potential new therapy for the treatment of gliomas.Anandamide induces cell death through lipid rafts in hepatic stellate cells.The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory.Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling.Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis.Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors.Exploring a role for heteromerization in GPCR signalling specificity.The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail.The therapeutic potential of cannabis in multiple sclerosis.Cannabinoids and cancer: pros and cons of an antitumour strategy.The dual neuroprotective-neurotoxic profile of cannabinoid drugs.CB(1) cannabinoid receptors and their associated proteins.Neurons on cannabinoids: dead or alive?Cannabinoid receptor systems: therapeutic targets for tumour intervention.WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture.The endocannabinoid system: a general view and latest additionsLasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain.New horizons for newborn brain protection: enhancing endogenous neuroprotectionThe potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma.Decreased frontal N-acetylaspartate levels in adolescents concurrently using both methamphetamine and marijuana.Cyclooxygenase-2 in synaptic signaling.The endocannabinoid system and sex steroid hormone-dependent cancers.Structure-activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1).Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression.The multiplicity of action of cannabinoids: implications for treating neurodegeneration.Cannabinoids: well-suited candidates for the treatment of perinatal brain injury.Using the endocannabinoid system as a neuroprotective strategy in perinatal hypoxic-ischemic brain injury.The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe?
P2860
Q24529892-C6446E5B-E00A-4383-B142-B1E7E82835A2Q24648473-9ED31F43-4B3C-4766-A05E-D13596A0AB98Q24814542-D30636DE-F85B-41BE-8E03-D5AD421C7DA3Q26740518-856ED58A-B8CA-45E7-BC43-63E6AA5E22D9Q26777055-526D18B6-A8A3-4C9A-9858-7CFE5845A7FDQ27310866-364428BB-C3FF-470E-94D9-34C2CAA7C4FAQ28578074-31819F66-F378-4A3C-83EA-27CB480804F7Q30370881-C6AEE268-A8F4-45CF-A8E5-00D8E6E6E6E2Q30391852-80F8EB91-1CF5-4744-BFAD-BC5DFE096340Q30499515-5B80F337-84D5-4794-92FF-814CFF59EDC9Q33310983-E8484BE4-FDD1-4C82-AFC5-8C5C915AC607Q33522772-37B7865D-5270-42EB-A89D-4C22FAF4A04DQ33623423-F8814BD4-B858-4B8E-97BF-43197BEE084BQ34070354-2FCA5D14-0744-43E5-98AA-7B6402BC8DEEQ34125281-3D2F624B-18DA-4D74-B054-A5277382F9A7Q34352311-9B9ACC84-D51C-4079-9DFD-DA36A0FF4D75Q34358271-DAD35931-BEE1-4092-931A-9EB05DAA2232Q34610463-D0D4CBCB-DAAF-4AD5-A18E-76F300F4BEADQ34660378-67D1F6EF-9699-4055-8827-3424C050007CQ34663357-6F14BF47-1FC3-4095-869B-AB77D327F007Q35094657-B30FA708-1844-4F7E-9644-D1E58B2ED6DBQ35100892-7B868463-DC0C-41CC-B3AD-A40D8A79DB1BQ35193273-66B3E1F4-29E8-42F6-8402-231CB9497785Q35232109-E72B1A12-3D14-4889-956D-6B5015A1A9D3Q35548960-6A00F567-2896-463C-A61C-BFA6519FA3DDQ35593944-E1C1BA8F-CD38-4D44-9800-AD7D9CA18B00Q35601542-3818CB54-4D39-4349-A3D2-09D8F232E4FBQ35639524-EF0D1381-D826-4056-902B-6539F9E5A09BQ35655078-EFB204EE-21E8-491F-ABC6-C7432E5EEAF8Q36374839-E08CABFD-F4FE-4F59-9779-32FF097A0CE4Q36575297-CA4B7473-25FB-4766-BBBC-F26F3F88FEBDQ36891392-0C7EAEEF-1BA3-491C-9443-336D038C477EQ36922736-20F0A455-0EDE-43E4-B52C-30E44D6D191FQ37393042-7C0707DF-77CC-4BDF-8A95-E77A6A6F7A05Q37432662-0ADBCF8B-5D73-463E-AF2E-D063BB96B956Q37490376-D779D1F1-515C-4640-905F-A3D2302A6669Q37793366-3436E9CD-C41D-42FB-AF19-30E9185D1D14Q38222889-475C95BD-D78C-486D-94CC-3B3078BFE436Q38248001-877B7DFE-CE22-4710-9497-D63F84B85E99Q38455748-26EBB7B1-E338-4C04-ADCB-79DA7ACD73AC
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cannabinoids and cell fate.
@ast
Cannabinoids and cell fate.
@en
Cannabinoids and cell fate.
@nl
type
label
Cannabinoids and cell fate.
@ast
Cannabinoids and cell fate.
@en
Cannabinoids and cell fate.
@nl
prefLabel
Cannabinoids and cell fate.
@ast
Cannabinoids and cell fate.
@en
Cannabinoids and cell fate.
@nl
P1476
Cannabinoids and cell fate
@en
P2093
Ismael Galve-Roperh
Manuel Guzmán
P304
P356
10.1016/S0163-7258(02)00256-5
P577
2002-08-01T00:00:00Z